Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Accenture
US Army
Chubb
Deloitte
Queensland Health
Colorcon
UBS
Boehringer Ingelheim

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,060,992

« Back to Dashboard

Which drugs does patent 9,060,992 protect, and when does it expire?

Patent 9,060,992 protects GATTEX KIT and is included in one NDA.

This patent has seven patent family members in seven countries.
Summary for Patent: 9,060,992
Title:Treatment of short bowel syndrome patients with colon-in-continuity
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Inventor(s): Sanguinetti; Elizabeth Lemaire (Salt Lake City, UT), Marriott; Thomas B. (Sandy, UT), Lopansri; Jennifer (Salt Lake City, UT), Blosch; Consuelo Maria (Mercer Island, WA)
Assignee: NPS Pharmaceuticals, Inc. (Bedminster, NJ)
Application Number:12/938,117
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,060,992

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Nps Pharms Inc GATTEX KIT teduglutide recombinant POWDER;SUBCUTANEOUS 203441-001 Dec 21, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,060,992

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,545,434 Treatment of short bowel syndrome patients with colon-in-continuity ➤ Sign Up
9,545,435 Treatment of short bowel syndrome patients with colon-in-continuity ➤ Sign Up
9,555,079 Treatment of short bowel syndrome patients with colon-in-continuity ➤ Sign Up
7,847,061 Treatment of short bowel syndrome patients with colon-in-continuity ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Baxter
Teva
Farmers Insurance
Fish and Richardson
Julphar
UBS
Mallinckrodt
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.